TY - JOUR
T1 - Thalassemia in Indonesia
AU - Wahidiyat, Pustika A.
AU - Sari, Teny T.
AU - Rahmartani, Ludi D.
AU - Iskandar, Stephen D.
AU - Pratanata, Anastasia M.
AU - Yapiy, Ivana
AU - Setianingsih, Iswari
AU - Atmakusuma, Tubagus D.
AU - Lubis, Anna M.
N1 - Funding Information:
This Special Issue on Thalassemia in Asia 2021 was partially supported by Project KY202002008 from the Ministry of Science and Technology of the People’s Republic of China through the Asian Thalassemia Training Center (ATTC) at Guangxi Medical University, Nanning, Guangxi, PRC.
Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Indonesia is located along the ‘Thalassemia Belt’ and a hotspot for hemoglobinopathies. Around 3.0–10.0% of the population carry β-thalassemia (β-thal) and 2.6–11.0% of the population carry α-thalassemia (α-thal). It is estimated that around 2500 babies are born with β-thal major (β-TM) each year. At present, the cornerstone of treatment for β-TM in Indonesia remains supportive, including blood transfusions and iron chelation therapy. Hemovigilance systems in some cities are poor and it increases the risk of transfusion-transmitted infections and transfusion reactions. The availability of iron chelators remains uncertain, even in some rural areas, iron chelators do not exist. The poor adherence to iron chelation therapy and maintaining pretransfusion hemoglobin (Hb) levels above 9.0 g/dL are still a major issue in Indonesia. The cost of blood transfusion and iron chelation are covered by national health insurance. In line with the rise of life expectancy, the financial burden of thalassemia in Indonesia is increasing sharply. Thus, optimizing preventive programs may be the most suitable option for the current thalassemia condition in Indonesia.
AB - Indonesia is located along the ‘Thalassemia Belt’ and a hotspot for hemoglobinopathies. Around 3.0–10.0% of the population carry β-thalassemia (β-thal) and 2.6–11.0% of the population carry α-thalassemia (α-thal). It is estimated that around 2500 babies are born with β-thal major (β-TM) each year. At present, the cornerstone of treatment for β-TM in Indonesia remains supportive, including blood transfusions and iron chelation therapy. Hemovigilance systems in some cities are poor and it increases the risk of transfusion-transmitted infections and transfusion reactions. The availability of iron chelators remains uncertain, even in some rural areas, iron chelators do not exist. The poor adherence to iron chelation therapy and maintaining pretransfusion hemoglobin (Hb) levels above 9.0 g/dL are still a major issue in Indonesia. The cost of blood transfusion and iron chelation are covered by national health insurance. In line with the rise of life expectancy, the financial burden of thalassemia in Indonesia is increasing sharply. Thus, optimizing preventive programs may be the most suitable option for the current thalassemia condition in Indonesia.
KW - Indonesia
KW - Iron chelation
KW - prevention
KW - thalassemia
UR - http://www.scopus.com/inward/record.url?scp=85135957566&partnerID=8YFLogxK
U2 - 10.1080/03630269.2021.2023565
DO - 10.1080/03630269.2021.2023565
M3 - Review article
C2 - 35950580
AN - SCOPUS:85135957566
SN - 0363-0269
VL - 46
SP - 39
EP - 44
JO - Hemoglobin
JF - Hemoglobin
IS - 1
ER -